Human atrial natriuretic peptide increased urinary production in patients with immunosuppressant-induced acute renal failure after transplantation: A report of three cases

Abstract

Nephrotoxicity is one of the most serious adverse effects of immunosuppresive agents and it may interfere with the anti-rejection therapy following organ transplantation. Human atrial natriuretic peptide (hANP) is known to have renal protective properties to accerate urine production, the mechanisms of which are attributable to dilatation of renal arteries and relaxation of messangial cells. By infusing hANP we successfully treated three cases of serious acute renal failure which were refractory to the conventional therapies. These results suggest that hANP is a possible additional modality for acute renal failure following organ transplantation.